{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:05:11Z","timestamp":1789632311322,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01118-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:45:12Z","timestamp":1788191112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG PET\/CT metabolic parameter to predict pathological complete response and survival after neoadjuvant immunotherapy plus chemoradiotherapy in resectable esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Jichen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"27","key":"1118_CR1","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. JCO. 2018;36(27):2796\u2013803. https:\/\/doi.org\/10.1200\/JCO.2018.79.1483.","journal-title":"JCO"},{"issue":"4","key":"1118_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.thorsurg.2022.06.003","volume":"32","author":"S Lewis","year":"2022","unstructured":"Lewis S, Lukovic J. Neoadjuvant therapy in esophageal cancer. Thorac Surg Clin. 2022;32(4):447\u201356. https:\/\/doi.org\/10.1016\/j.thorsurg.2022.06.003.","journal-title":"Thorac Surg Clin"},{"issue":"4","key":"1118_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction cancers, version 2. 2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2023;21(4):393\u2013422. https:\/\/doi.org\/10.6004\/jnccn.2023.0019.","journal-title":"J Natl Compr Cancer Network"},{"issue":"3","key":"1118_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jtcvs.2021.12.054","volume":"165","author":"M De Silva Sewastjanow","year":"2023","unstructured":"De Silva Sewastjanow M, Rogers JE, Hofstetter WL, Ajani JA. Esophageal cancer: is the CROSS strategy ready for history books? The J Thorac Cardiovasc Surg. 2023;165(3):901\u201305. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.12.054.","journal-title":"The J Thorac Cardiovasc Surg"},{"issue":"18","key":"1118_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. JCO. 2021;39(18):1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614.","journal-title":"JCO"},{"issue":"3","key":"1118_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jtcvs.2022.08.009","volume":"165","author":"D Chen","year":"2023","unstructured":"Chen D, Kong M, Sun J, Yang H, Chen Y, Fang W, et al. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: results from the phase III trial NEOCRTEC5010. The J Thorac Cardiovasc Surg. 2023;165(3):888\u201397. https:\/\/doi.org\/10.1016\/j.jtcvs.2022.08.009.","journal-title":"The J Thorac Cardiovasc Surg"},{"issue":"8","key":"1118_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156(8):721\u201329. https:\/\/doi.org\/10.1001\/jamasurg.2021.2373.","journal-title":"JAMA Surg"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","volume":"144","author":"C Li","year":"2021","unstructured":"Li C, Zhao S, Zheng Y, Han Y, Chen X, Cheng Z, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer (Oxford, Engl: 1990). 2021;144:232\u201341. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.039.","journal-title":"Eur J Cancer (Oxford, Engl: 1990)"},{"issue":"12","key":"1118_CR9","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, et al. Neoadjuvant chemoradiotherapy combined with Atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin Cancer Res. 2021;27(12):3351\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4443.","journal-title":"Clin Cancer Res"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","volume":"103","author":"X Yan","year":"2022","unstructured":"Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int J Surg. 2022;103:106680. https:\/\/doi.org\/10.1016\/j.ijsu.2022.106680.","journal-title":"Int J Surg"},{"issue":"15","key":"1118_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.21037\/atm-21-3352","volume":"9","author":"G Yang","year":"2021","unstructured":"Yang G, Su X, Yang H, Luo G, Gao C, Zheng Y, et al. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma. Ann Transl Med. 2021;9(15):1254. https:\/\/doi.org\/10.21037\/atm-21-3352.","journal-title":"Ann Transl Med"},{"key":"1118_CR12","doi-asserted-by":"publisher","unstructured":"Hipp J, Kuvendjiska J, Hillebrecht HC, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, et al. Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study. Dis The Esophagus. 2023;36(7):doac095. https:\/\/doi.org\/10.1093\/dote\/doac095.","DOI":"10.1093\/dote\/doac095"},{"issue":"4","key":"1118_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/jso.25846","volume":"121","author":"W Lutfi","year":"2020","unstructured":"Lutfi W, Martinez-Meehan D, Dhupar R, Christie N, Sarkaria I, Ekeke C, et al. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival. J Surg Oncol. 2020;121(4):654\u201361. https:\/\/doi.org\/10.1002\/jso.25846.","journal-title":"J Surg Oncol"},{"issue":"2","key":"1118_CR14","doi-asserted-by":"publisher","first-page":"189572","DOI":"10.1016\/j.bbcan.2026.189572","volume":"1881","author":"W Zhao","year":"2026","unstructured":"Zhao W, Wang SQ, Lv H, Gao S, Chen XB. Current research status and challenges of neoadjuvant immunotherapy for esophageal squamous cell carcinoma. Biochim et Biophys Acta (BBA) - Rev Cancer. 2026;1881(2):189572. https:\/\/doi.org\/10.1016\/j.bbcan.2026.189572.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"1764960","DOI":"10.3389\/fimmu.2026.1764960","volume":"17","author":"M Sun","year":"2026","unstructured":"Sun M, Yang P, Qi L, Yang T, Wang W, Yu Y, et al. Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study. Front Immunol. 2026;17:1764960. https:\/\/doi.org\/10.3389\/fimmu.2026.1764960.","journal-title":"Front. Immunol"},{"issue":"12","key":"1118_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/15384047.2020.1834319","volume":"21","author":"D Sun","year":"2020","unstructured":"Sun D, Liu D, Liu Q, Hou H. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma. Cancer Biol Ther. 2020;21(12):1097\u2013104. https:\/\/doi.org\/10.1080\/15384047.2020.1834319.","journal-title":"Cancer Biol Ther"},{"key":"1118_CR17","doi-asserted-by":"publisher","unstructured":"Wang W, Wu M, Liu M, Yan Z, Wang G, Mao D, et al. Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication. J Immunother Cancer. 2020;8(1):e000793. https:\/\/doi.org\/10.1136\/jitc-2020-000793.","DOI":"10.1136\/jitc-2020-000793"},{"issue":"1","key":"1118_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12876-024-03382-w","volume":"24","author":"N Hokamura","year":"2024","unstructured":"Hokamura N, Fukagawa T, Fukushima R, Kiyokawa T, Horikawa M, Soeda N, et al. Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma. BMC Gastroenterol. 2024;24(1):295. https:\/\/doi.org\/10.1186\/s12876-024-03382-w.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"1118_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1021\/acs.jproteome.3c00527","volume":"23","author":"W Lin","year":"2024","unstructured":"Lin W, Si X, Zhao Z, Chen F, Xu J, Huang W, et al. Applying untargeted lipidomics to evaluate the efficacy of combined neoadjuvant chemotherapy and immunotherapy for esophageal squamous carcinoma treatment. J Proteome Res. 2024;23(2):663\u201372. https:\/\/doi.org\/10.1021\/acs.jproteome.3c00527.","journal-title":"J Proteome Res"},{"issue":"3","key":"1118_CR20","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00330-024-11141-4","volume":"35","author":"L Shi","year":"2024","unstructured":"Shi L, Li C, Bai Y, Cao Y, Zhao S, Chen X, et al. CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Eur Radiol. 2024;35(3):1594\u2013604. https:\/\/doi.org\/10.1007\/s00330-024-11141-4.","journal-title":"Eur Radiol"},{"issue":"6","key":"1118_CR21","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.7150\/jca.105171","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Gao F, Wu S, Wang H, Dang W, Sun M, et al. A machine learning model utilizing CT radiomics features and peripheral blood inflammatory markers predicts the prognosis of patients with unresectable esophageal squamous cell carcinoma undergoing PD-1 inhibitor combined with concurrent chemoradiotherapy. J Cancer. 2025;16(6):2001\u201314. https:\/\/doi.org\/10.7150\/jca.105171.","journal-title":"J Cancer"},{"issue":"4","key":"1118_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3322\/caac.21399","volume":"67","author":"TW Rice","year":"2017","unstructured":"Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction\u2014Major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clinicians. 2017;67(4):304\u201317. https:\/\/doi.org\/10.3322\/caac.21399.","journal-title":"CA Cancer J Clinicians"},{"issue":"2","key":"1118_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, Engl: 1990). 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer (Oxford, Engl: 1990)"},{"issue":"1","key":"1118_CR24","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.1038\/s41598-021-90753-y","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Lin JW, Yeh HL, Chuang CY, Chen CC. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. Sci Rep. 2021;11(1):11626. https:\/\/doi.org\/10.1038\/s41598-021-90753-y.","journal-title":"Sci Rep"},{"issue":"2","key":"1118_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-021-05487-w","volume":"49","author":"Y Choi","year":"2022","unstructured":"Choi Y, Choi JY, Hong TH, Choi YL, Oh D, Woo SY, et al. Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET\/CT in patient management and prognostication. Eur J Nucl Med Mol Imag. 2022;49(2):751\u201362. https:\/\/doi.org\/10.1007\/s00259-021-05487-w.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"1118_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1245\/s10434-023-14352-z","volume":"31","author":"HH Wang","year":"2024","unstructured":"Wang HH, Steffens EN, Kats-Ugurlu G, van Etten B, Burgerhof JGM, Hospers GAP, et al. Potential predictive immune and metabolic biomarkers of tumor microenvironment regarding pathological and clinical response in esophageal cancer after Neoadjuvant Chemoradiotherapy: a systematic review. Ann Surg Oncol. 2024;31(1):433\u201351. https:\/\/doi.org\/10.1245\/s10434-023-14352-z.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1118_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00259-016-3478-2","volume":"44","author":"PSN van Rossum","year":"2017","unstructured":"van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, et al. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imag. 2017;44(1):71\u201380. https:\/\/doi.org\/10.1007\/s00259-016-3478-2.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"1118_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bulcan.2016.11.010","volume":"104","author":"N Radosevic-Robin","year":"2017","unstructured":"Radosevic-Robin N, B\u00e9guinot M, Penault-Llorca F. \u00c9valuation de l\u2019infiltrat immun dans le cancer du sein [Evaluation of the immune infiltrate in breast cancer]. B Cancer. 2017;104(1):52\u201368. https:\/\/doi.org\/10.1016\/j.bulcan.2016.11.010.","journal-title":"B Cancer"},{"issue":"7","key":"1118_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3760\/cma.j.cn112151-20201224-00962","volume":"50","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhang LP, Hou LK, Dong ZW, Zhang W, Wu W, et al. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy]. Zhonghua Bing Li Xue Za Zhi. 2021;50(7):773\u201378. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20201224-00962.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"7","key":"1118_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jtho.2019.04.004","volume":"14","author":"DJJM de Gouw","year":"2019","unstructured":"de Gouw DJJM, Klarenbeek BR, Driessen M, Bouwense SAW, van Workum F, F\u00fctterer JJ, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis. J Thorac Oncol. 2019;14(7):1156\u201371. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.004.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1118_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/SLA.0000000000003397","volume":"271","author":"BM Eyck","year":"2020","unstructured":"Eyck BM, Onstenk BD, Noordman BJ, Nieboer D, Spaander MCW, Valkema R, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Ann Surg. 2020;271(2):245\u201356. https:\/\/doi.org\/10.1097\/SLA.0000000000003397.","journal-title":"Ann SurgAnnals Surg"},{"issue":"1","key":"1118_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13014-023-02224-5","volume":"18","author":"L Xia","year":"2023","unstructured":"Xia L, Li X, Zhu J, Gao Z, Zhang J, Yang G, et al. Prognostic value of baseline 18F-FDG PET\/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy. Radiat Oncol. 2023;18(1):41. https:\/\/doi.org\/10.1186\/s13014-023-02224-5.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1118_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12880-019-0401-x","volume":"20","author":"S Mantziari","year":"2020","unstructured":"Mantziari S, Pomoni A, Prior JO, Winiker M, Allemann P, Demartines N, et al. 18F- FDG PET\/CT-derived parameters predict clinical stage and prognosis of esophageal cancer. BMC Med Imag. 2020;20(1):7. https:\/\/doi.org\/10.1186\/s12880-019-0401-x.","journal-title":"BMC Med Imag"},{"issue":"Suppl S5","key":"1118_CR34","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1245\/s10434-011-1738-8","volume":"23","author":"LM Schreurs","year":"2016","unstructured":"Schreurs LM, Janssens AC, Groen H, Fockens P, van Dullemen HM, van Berge Henegouwen MI, et al. Value of EUS in determining curative resectability in reference to CT and FDG-PET: the optimal sequence in preoperative staging of esophageal cancer? Ann Surg Oncol. 2016;23(Suppl S5):1021\u201328. https:\/\/doi.org\/10.1245\/s10434-011-1738-8.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1118_CR35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/cancers12030607","volume":"12","author":"CH Lin","year":"2020","unstructured":"Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, et al. Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in esophageal squamous cell carcinoma treated with definitive Chemoradiotherapy. Cancers (Basel). 2020;12(3):607. https:\/\/doi.org\/10.3390\/cancers12030607.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1118_CR36","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12149-024-01933-5","volume":"38","author":"WK Yap","year":"2024","unstructured":"Yap WK, Hsu KH, Wang TH, Lin CH, Kang CJ, Huang SM, et al. The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis. Ann Nucl Med. 2024;38(8):607\u201318. https:\/\/doi.org\/10.1007\/s12149-024-01933-5.","journal-title":"Ann Nucl Med"},{"key":"1118_CR37","doi-asserted-by":"publisher","first-page":"1266843","DOI":"10.3389\/fimmu.2023.1266843","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ren J. 18F-FAPI-04 PET\/CT parameters predict PD-L1 expression in esophageal squamous cell carcinoma. Front Immunol. 2023;14:1266843. https:\/\/doi.org\/10.3389\/fimmu.2023.1266843.","journal-title":"Front. Immunol"},{"issue":"11","key":"1118_CR38","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.3390\/biomedicines11113072","volume":"11","author":"WK Yap","year":"2023","unstructured":"Yap WK, Hsiao IT, Yap WL, Tsai TY, Lu YA, Yang CK, et al. A radiotherapy dose map-guided deep learning method for predicting pathological complete response in esophageal cancer patients after neoadjuvant chemoradiotherapy followed by surgery. Biomedicines. 2023;11(11):3072. https:\/\/doi.org\/10.3390\/biomedicines11113072. PMID: 38002072.","journal-title":"Biomedicines"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01118-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01118-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01118-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:34:31Z","timestamp":1789630471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01118-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01118-5","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of our institution and with the principles of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients enrolled in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirms that the human research participants provided informed consent for the publication of the images in Figures.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}